No­vo’s kid­ney dis­ease win for Ozem­pic adds to case for ex­pand­ed use in di­a­bet­ic pa­tients

No­vo Nordisk’s semaglu­tide sig­nif­i­cant­ly re­duced the risk of car­dio­vas­cu­lar events and death in pa­tients with type 2 di­a­betes and chron­ic kid­ney dis­ease in a late-stage test, po­ten­tial­ly open­ing up a new car­diometa­bol­ic mar­ket op­por­tu­ni­ty.

The com­pa­ny on Tues­day re­vealed semaglu­tide had met the Phase III FLOW tri­al’s com­pos­ite pri­ma­ry end­point, re­duc­ing pa­tients’ risk of kid­ney dis­ease pro­gres­sion as well as car­dio­vas­cu­lar and kid­ney death of 24% ver­sus place­bo, per a com­pa­ny re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER